Anti-asthmatic properties of a new peroral drug (HC 20-5II).

Abstract

A clinical trial was performed with a new substance (HC 20-511) derived from the cycloheptothiophene group used in the management of asthma. Twenty-four asthma patients were treated at random, with HC 20-511 or placebo or the antihistaminic substance, clemastin (Tavegyl). A statistical evaluation of the results unequivocally demonstrates good protection with a single dose of 2.0 mg or two times 1.0 mg for 3 days against a challenging antigen, compared with the placebo or the antihistaminic agent. Tolerance was excellent.

• Authors: J P Girard, M Cuevas
• Journal: Acta allergologica (Acta Allergol) Vol. 32 Issue 1 Pg. 27-34 (Feb 1977) ISSN: 0001-5148 [Print] Denmark
• PMID: 320807 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Cycloheptanes
• Piperidines
• Placebos
• Thiophenes
• Clemastine

Topics

• Adolescent
• Adult
• Asthma (drug therapy)
• Clemastine (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Cycloheptanes (adverse effects)
• Female
• Forced Expiratory Volume
• Humans
• Male
• Middle Aged
• Piperidines (therapeutic use)
• Placebos
• Thiophenes (adverse effects, therapeutic use)
• Vital Capacity